Opendata, web and dolomites

SAMPA SIGNED

Scale-up of an Advanced Manufacturing process to produce a Pharmaceutical product Application (SAMPA).

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "SAMPA" data sheet

The following table provides information about the project.

Coordinator
SIGMOID PHARMA LIMITED 

Organization address
address: THE INVENT CENTRE, DUBLIN CITY UNIVERSITY
city: DUBLIN
postcode: 9
website: www.sigmoidpharma.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website https://www.sublimitytherapeutics.com/about/sampa-grant/
 Total cost 2˙307˙500 €
 EC max contribution 1˙600˙000 € (69%)
 Programme 1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
2. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SIGMOID PHARMA LIMITED IE (DUBLIN) coordinator 1˙600˙000.00

Map

 Project objective

Sigmoid Pharma has developed an innovative product, CyCol®, to treat patients with moderate-severe ulcerative colitis, a disease that affects 1 million patients in Europe. CyCol® is enabled using Sigmoid’s proprietary SmPill® nanoemulsion-based technology to target a known and powerful drug, cyclosporine, directly to inflamed colons. In Phase II human studies, CyCol® was proven to be effective and safe. CyCol®, on oral product, will compete with injected, expensive drugs that have a risk of serious side effects.

Successful development and commercialisation of CyCol® will pivot on scaling up the advanced manufacturing process from the current ~5kg to the ~50kg batch size required for Phase III human studies.

SAMPA (Scale-up of an Advanced Manufacturing process to produce a Pharmaceutical product Application) project is focused on achieving 50kg batches. It will involve leading EU-based specialist SME technology and equipment suppliers as well as a number of knowledge providers. The requested budget is €1.6M and will be completed in 21 months.

Successful completion of this project will retain and enhance intellectual property and know-how in Sigmoid, increase long term high skill jobs. In parallel, the project will unlock the value inherent not only of CyCol®, but also the underlying SmPill® technology platform. Furthermore, the project will increase the probability of overall company success and increase significantly the NPV to more than €500M.

 Deliverables

List of deliverables.
Project website Websites, patent fillings, videos etc. 2019-11-28 17:28:20

Take a look to the deliverables list in detail:  detailed list of SAMPA deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAMPA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAMPA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.1.;H2020-EU.2.1.2.)

S3D (2015)

Feasibility study to determine the use of ITS technology to replace nuclear density meters in mining, dredging and other areas of hydraulic transport.

Read More  

NANOHIGH (2015)

High volume production facility for high accuracy nanocapsules

Read More  

InLineNano (2015)

In-Line Areal Surface Measurement for Micro and Nano Production

Read More